Dr Jean Suzanne Cannon, MD | |
2510 Chickasaw Blvd, Ardmore, OK 73401 | |
(580) 226-8181 | |
(580) 223-4761 |
Full Name | Dr Jean Suzanne Cannon |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 2510 Chickasaw Blvd, Ardmore, Oklahoma |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1386815421 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 25555 (Oklahoma) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Jean Suzanne Cannon, MD 2510 Chickasaw Blvd, Ardmore, OK 73401 Ph: (580) 226-8181 | Dr Jean Suzanne Cannon, MD 2510 Chickasaw Blvd, Ardmore, OK 73401 Ph: (580) 226-8181 |
News Archive
Thomas Perls, MD, MPH, a geriatrician at Boston Medical Center (BMC) and professor of medicine at Boston University School of Medicine (BUSM), has been honored with the Ewald W. Busse Research Award.
Speaking at the UK National Stem Cell Network Annual Science Meeting in Edinburgh, Professor Silvia Marino shows how the mechanisms normally involved in balancing different functions of stem cells may also contribute to cancer.
A rogue industry. A gun to our head. Extortion. That's how infuriated lawmakers described soft drink companies — and what they pulled off in 2018 when they scored a legislative deal that bars California's cities and counties from imposing taxes on sugary drinks.
The Obama government is all set to ignore the food pyramid, that symbol of healthy eating for the last two decades. In its place officials are dishing up a simple, plate-shaped symbol, sliced into wedges for the basic food groups and half-filled with fruits and vegetables.
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.
› Verified 7 days ago